Eftilagimod alpha (soluble LAG-3 protein) combined with pembrolizumab as second-line therapy for patients with metastatic head and neck squamous cell carcinoma.

Martin Forster Irene Brana Antonio L Pousa Bernard Doger Patricia Roxburgh Pawan Bajaj Julio Antonio Peguero Matthew G Krebs Enric Carcereny Grisma Patel Christian Mueller Chrystelle Brignone Frederic Triebel

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Efti plus pembrolizumab was safe and showed encouraging antitumor activity and pharmacodynamic effects in 2nd line HNSCC patients, thus supporting further evaluation of this combination in earlier treatment lines.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
advanced non small cell lung cancer
prognostic factors
patient reported outcomes
replacement therapy
smoking cessation
patient reported